Sanger Institute cancer researcher’s innovation recognised

Congratulations to Dr Mathew Garnett who has received a National Cancer Research Institute Excellence Award for his research into the use of next-generation organoid models of cancer

Sanger Institute cancer researcher’s innovation recognised

Mathew Garnett has received a National Cancer Research Institute Excellence Award

Dr Mathew Garnett has received one of the first Excellence Awards given by the National Cancer Research Institute (NCRI). The Innovation Award highlights the work of Dr Garnett and his team in producing hundreds of patient-derived 3D organoid cultures as a community resource to accelerate cancer research.

The Garnett group at the Wellcome Sanger Institute have created hundreds of organoids – 3D clusters of cells derived from patients’ tumours that are grown in the laboratory to represent a patient’s cancer. Using these organoids, the team are investigating the genetic causes of several different types of cancer, including breast, oesophageal, colon and lung cancers.

Dr Garnett and his team are using these organoids* to investigate the susceptibility of various cancer subtypes to panels of different drugs. They aim to understand the genetic changes that make certain cancers respond to drugs and others not, and pin down genes that are essential for each cancer’s survival to serve as new drug targets.

Through the use of organoid technology, genome sequencing, gene knock-out experiments and drug testing, Dr Garnett and his team are identifying the weak spots of different cancers. As a result of this work, new guidelines for the future of precision cancer treatments will be created and shared in the form of the Cancer Dependency Map** - a detailed rulebook of precision cancer treatments to help more patients receive effective therapies.

To recognise the scientific advances made by Dr Garnett and his team, he was awarded an Innovation Award by the NCRI after being nominated by Dr Alexandra Bonner, Head of Research Resources at Breast Cancer Now.

“It is an enormous honour to receive the NCRI Innovation award on behalf of the dedicated team members involved in this research. The use of organoids has already begun to provide insights into the mechanisms underpinning the causes of cancer and how we might develop better treatments for patients.”

Dr Mathew Garnett, from the Wellcome Sanger Institute

 


The Awards have been created to celebrate the 15th year anniversary of the NCRI Cancer Conference and are directly linked to the key strategic objectives of the partnership, which aims to accelerate progress in cancer research through collaboration.

“We are delighted to recognise and honour the achievements made by these individuals and teams who have worked effortlessly in the community to help accelerate progress in cancer research for the benefit of patients and society.”

Dr Iain Frame, CEO of National Cancer Research Institute (NCRI)

The Awards will be presented on Monday 4th November at the NCRI Cancer Conference taking place in Glasgow at the Scottish Event Campus.

Notes to Editors

* Data on the cancer tissue organoids, such as drug susceptibility and genomic data are available to researchers worldwide on the Cell Model Passports website and provide a powerful new tool to enable studies into cancer development and drug discovery. https://cellmodelpassports.sanger.ac.uk/

** The Cancer Dependency Map at the Sanger Institute is a project with four components – drugs, models, genes and analytics – which together contribute to the production of a rulebook for the precision treatment of cancer. https://depmap.sanger.ac.uk/

Mapping the dependencies of cancers is an international effort by the Sanger Institute in the UK and the Broad Institute in the United States. Researchers aim to bridge the translational gap that exists between genomic sequencing and providing precision medicine to the many cancer patients. Genes that are critical to a cancer’s survival represent dependencies: vulnerabilities that might serve as targets for designing new therapies or repurposing existing ones. Mapping these dependencies is essential to making precision cancer medicine a reality.

Selected Websites
The weird and wonderful world of organoidsSanger ScienceThe weird and wonderful world of organoids
Mini organs grown in the lab are boosting cancer research and drug discovery.

Is cancer a genetic disease?FactsIs cancer a genetic disease?
Cancer is the most common human genetic disease. The transition from a normal cell to a malignant cancer is driven by changes to a cell’s DNA, also known as mutations.

Role of Cancer GenesVideoRole of Cancer Genes
This flash animation shows you how DNA mutations are involved in the development of cancer. 

Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

Appointments and changes to the Genome Research Limited Board
At the GRL Board meeting on 2 December 2019, David Willetts announced his intention to step down as Chair because of his extensive commitments across the academic and science sectors. Wellcome's Director, Jeremy Farrar, will take over the Chair of GRL Board from 1 January 2020.
Researchers identify new possibilities for the treatment of inflammatory bowel disease
Two molecular pathways found to be integral to maintaining balance in the digestive system
Root of childhood kidney cancer discovered
Pre-cancerous signatures found in healthy tissue point the way towards new treatment options